Lucid Diagnostics Inc. (NASDAQ: LUCD)

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company that focuses on the early detection of esophageal adenocarcinoma in patients with gastroesophageal reflux disease. The company’s core offering is the EsoGuard Esophageal DNA Test which is performed on cells collected by the EsoCheck Esophageal Cell Collection Device. EsoGuard is a bisulfite converted targeted next generation sequencing assay that measures methylation at 31 sites on two genes to identify Barrett’s esophagus and dysplasia. The technology is designed to be noninvasive patient friendly and suitable for use in a physician office setting. Lucid Diagnostics leverages patents licensed from Case Western Reserve University and has obtained FDA 510(k) clearance for EsoCheck and Breakthrough Device designation for EsoGuard. The company operates a network of owned test centers satellite testing events and telemedicine partnerships to broaden patient access. Its wholly owned subsidiary LucidDx Labs runs a CLIA certified laboratory that performs the EsoGuard assay while another subsidiary CapNostics LLC holds additional assets related to the technology.

Lucid Diagnostics generates revenue primarily from the sale of the EsoGuard Esophageal DNA Test which is performed together with the EsoCheck collection device. The company bills Medicare private insurers and self pay patients for each test performed. In addition Lucid has established direct contracts with large self insured employers unions and other organizations to provide testing services to their members. A cash pay program targeting concierge medicine practices offers an alternative payment route for patients who prefer out of pocket arrangements. Through a telemedicine partnership with UpScript LLC the company also accepts self referrals from direct to consumer marketing and bills the test accordingly. Revenue is further supported by the established Medicare payment rate of 1938 dollars effective January 2021 which provides a predictable reimbursement baseline for eligible patients. Lucid also sells specimen kits and related consumables to healthcare providers who wish to collect samples on site and send them to the laboratory for analysis.

Lucid Diagnostics occupies a niche within the broader gastrointestinal diagnostics market as the first and only commercially available test designed for widespread noninvasive screening of Barrett’s esophagus in at risk GERD patients. Its main competitors include traditional upper endoscopy procedures and emerging devices such as the EndoSponge Cytosponge and other investigational tools that aim to collect esophageal cells without sedation. The company also faces competition from multicancer early detection blood tests that seek to identify multiple tumor types simultaneously. Lucid’s competitive advantages stem from its proprietary Collect and Protect technology which protects sampled cells from contamination the strong analytical and clinical performance of EsoGuard demonstrated in NIH funded studies and the favorable reimbursement landscape secured through Medicare coverage and Breakthrough Device designation. The company’s intellectual property portfolio anchored by patents licensed from Case Western Reserve University further reinforces its market position and creates barriers to entry for potential rivals. Management estimates that the total addressable market in the United States exceeds sixty billion dollars based on a Medicare reimbursement rate of approximately two thousand dollars and an eligible population of roughly thirty million individuals.

Lucid Diagnostics serves a diverse set of customers that includes primary care physicians gastroenterologists and other healthcare providers who order the EsoGuard test for their patients. The company also works directly with large self insured employers unions and other organizations that have contracted to offer testing to their members. Concierge medicine practices nationwide participate in Lucid’s cash pay program allowing patients to obtain the test outside traditional insurance channels. Through its telemedicine arrangement Lucid partners with UpScript LLC to accept self referrals from direct to consumer marketing and to process billing for those tests. Community outreach initiatives have included testing events with the San Antonio Fire Department and similar collaborations with fire departments across the country to raise awareness and provide access to the screening service. In addition Lucid reports that a number of regional health systems and physician groups have adopted the test as part of their preventive care programs.